MetLife (NYSE:MET) Price Target Raised to $96.00

MetLife (NYSE:MET) had its price objective increased by stock analysts at Barclays from $90.00 to $96.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the financial services provider’s stock. Barclays‘s target price would suggest a potential upside of 15.69% from the stock’s previous close.

MET has been the subject of several other reports. StockNews.com raised MetLife from a “hold” rating to a “buy” rating in a report on Wednesday, January 1st. Wells Fargo & Company boosted their target price on MetLife from $92.00 to $93.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Jefferies Financial Group lifted their target price on shares of MetLife from $89.00 to $95.00 and gave the company a “buy” rating in a report on Friday, September 27th. Piper Sandler raised their price objective on shares of MetLife from $85.00 to $92.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 2nd. Finally, TD Cowen increased their price objective on MetLife from $97.00 to $99.00 and gave the company a “buy” rating in a research note on Wednesday, November 27th. Fourteen investment analysts have rated the stock with a buy rating, According to MarketBeat, MetLife has an average rating of “Buy” and a consensus target price of $89.08.

MetLife Stock Up 0.9 %

MET stock traded up $0.77 during trading on Monday, hitting $82.98. 1,424,223 shares of the company’s stock were exchanged, compared to its average volume of 1,974,897. The business has a 50-day moving average price of $82.89 and a two-hundred day moving average price of $78.65. The company has a current ratio of 0.16, a quick ratio of 0.16 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $57.46 billion, a price-to-earnings ratio of 16.73, a PEG ratio of 0.76 and a beta of 1.07. MetLife has a 52-week low of $64.61 and a 52-week high of $89.05.

Institutional Trading of MetLife

A number of institutional investors and hedge funds have recently modified their holdings of the company. MeadowBrook Investment Advisors LLC boosted its stake in MetLife by 244.4% in the 3rd quarter. MeadowBrook Investment Advisors LLC now owns 310 shares of the financial services provider’s stock valued at $26,000 after buying an additional 220 shares in the last quarter. Carmichael Hill & Associates Inc. raised its holdings in shares of MetLife by 131.9% during the third quarter. Carmichael Hill & Associates Inc. now owns 327 shares of the financial services provider’s stock worth $27,000 after acquiring an additional 186 shares during the period. Wolff Wiese Magana LLC increased its stake in MetLife by 374.3% in the 3rd quarter. Wolff Wiese Magana LLC now owns 351 shares of the financial services provider’s stock valued at $29,000 after buying an additional 277 shares during the last quarter. Peterson Financial Group Inc. bought a new position in shares of MetLife in the 3rd quarter valued at about $30,000. Finally, Fortitude Family Office LLC lifted its position in MetLife by 177.3% during the third quarter. Fortitude Family Office LLC now owns 416 shares of the financial services provider’s stock worth $34,000 after acquiring an additional 266 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

About MetLife

MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.